With the second largest pharmaceutical market in the world, a wealthy and aging population, and a regulatory system that now rewards innovation, Japan has great appeal to foreign companies with novel pharmaceutical products. Nevertheless, cultural and linguistic barriers combined with medical, regulatory, and operational complexities, continue to keep foreign companies from integrating Japan into global development. As a result, Japanese new drug approvals continue to lag behind US/EU approvals by about 5 years.
